COVID-19 Information

Coronavirus2020image

CDC Updates Guidance on Interval Between COVID-19 Vaccine Doses

On January 21, 2021, the CDC updated its guidance regarding the interval between the two doses of the COVID-19 vaccines from Pfizer-BioNTech and Moderna. The CDC now advises that "the second dose of Pfizer-BioNTech and Moderna COVID-19 vaccines may be scheduled for administration up to 6 weeks (42 days) after the first dose." Additional text from the latest CDC guidanace is provided below.

Administration
The mRNA COVID-19 vaccine series consist of two doses administered intramuscularly:

Pfizer-BioNTech (30 µg, 0.3 ml each): 3 weeks (21 days) apart
Moderna (100 µg, 0.5 ml): 1 month (28 days) apart
Persons should not be scheduled to receive the second dose earlier than recommended (i.e., 3 weeks [Pfizer-BioNTech] or 1 month [Moderna]). However, second doses administered within a grace period of 4 days earlier than the recommended date for the second dose are still considered valid. Doses inadvertently administered earlier than the grace period should not be repeated.

The second dose should be administered as close to the recommended interval as possible. However, if it is not feasible to adhere to the recommended interval, the second dose of Pfizer-BioNTech and Moderna COVID-19 vaccines may be scheduled for administration up to 6 weeks (42 days) after the first dose. There are currently limited data on efficacy of mRNA COVID-19 vaccines administered beyond this window. If the second dose is administered beyond these intervals, there is no need to restart the series.

Vaccine administration errors should be reported to the Vaccine Adverse Event Reporting System (VAERS)

Read full guidance from the CDC.

For information on how to schedule an appointment to receive the COVID-19 vaccine in DC, visit the page DC COVID-19 Vaccination Process.

Streamlined PPP loan forgiveness form now available

The U.S. Small Business Administration has released a new one-page application for borrowers with Paycheck Protection Program loans of $150,000 or less.

Read the full story from ADA News ( January 20)

ADA Guidance on COVID-19 Vaccines in the Dental Workplace

The ADA has issues two new guidance documents on COVID-19 Vaccines in the Dental Workplace:

Beware of Counterfeit N95/KN95 Respirators and Other PPE

The COVID-19 pandemic and short supply of N95/KN95 masks, other PPE, and test kits combine to create increased potential for counterfeit products. You are urged to exercise caution when purchasing PPE, test kits and other supplies, particularly from suppliers you do not know. The CDC National Personal Protective Technology Laboratory (NPPTL) provides additional information about N95 masks and alternatives permitted during the pandemic (FDA Emergency Use Authorization (EUA)). NPPTL also provides information on counterfeit respirators. The NPPTL page also includes the following statement:

NIOSH has recently received new information from Stakeholders across the United States regarding products from China claiming to meet GB2626 and EN149. Assessment results confirm that some of these products have poor filter efficiency and are of poor quality. NIOSH is working closely with the FDA to align Emergency Use Authorizations to communicate the point of use testing results.

TDSC recently released two resources that provide guidance on this topic:

N95 Respirator FDA Authorized Cleaning Process

The FDA authorized Battelle to employ its Critical Care Decontamination System™ (CCDS). The CCDS can be used to decontaminate N95 masks (healthcare and industrial) that are not cellulose based. There is a CCDS facility in DC, and the decontamination service is being provided to healthcare personnel at no charge. Here is the form to request the Battelle CCDS service. Additional information on this program is provided below under “Additional Resources.”

The FDA Establishment Registration & Device Listing enables you to look up manufacturers who are registered to sell medical devices, including PPE, in the United States. If you search for “ORW” under product code as shown in the screenshot below, you will be provided with a list of manufacturers that registered with the FDA to sell KN95 in the United States. The presence of a manufacturer on the list is not a guarantee; searching for the manufacturer on the list should be a minimal check performed. The FDA has a toll-free information line open 24 hours a day where you can ask questions about COVID-19 Diagnostic Tests, and COVID-19 device shortages, including all Personal Protective Equipment for masks and respirators: 1-888-INFO-FDA.

Updated April 17, 2020

 

"State":"DC"